← Back to Clinical Trials
Recruiting NCT05325424

NCT05325424 The Effect of Laparoscopic Splenectomy on Liver Reserve Function for Cirrhosis Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05325424
Status Recruiting
Phase
Sponsor Northern Jiangsu People's Hospital
Condition Cirrhosis, Liver
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2022-03-01
Primary Completion 2025-07-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Laparoscopic splenectomy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2022-03-01 with a primary completion date of 2025-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this study, the investigators compared the improvement of liver reserve function related indicators in patients with liver cirrhosis after laparoscopic splenectomy. To determine whether surgical treatment can help enhance postoperative liver reserve function and improve patient prognosis.

Eligibility Criteria

Inclusion Criteria: * A clinical, radiological or histologic diagnosis of cirrhosis of any etiology * Splenomegaly with secondary hypersplenism, Platelet count \< 50\*10\^9/L * Informed consent to participate in the study Exclusion Criteria: * Hepatocellular carcinoma or any other malignancy, * Child-Pugh grade C * Recent peptic ulcer disease * History of Hemorrhagic stroke * Pregnancy. * Uncontrolled Hypertension * Bleeding portal hypertension * Human immunodeficiency virus (HIV) infection

Contact & Investigator

Central Contact

Guo-Qing Jiang, MD

✉ jgqing2003@hotmail.com

📞 +8651487373272

Principal Investigator

Guo-Qing Jiang, MD

STUDY CHAIR

Clinical Medical College of Yangzhou University

Frequently Asked Questions

Who can join the NCT05325424 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cirrhosis, Liver. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05325424 currently recruiting?

Yes, NCT05325424 is actively recruiting participants. Contact the research team at jgqing2003@hotmail.com for enrollment information.

Where is the NCT05325424 trial being conducted?

This trial is being conducted at Yangzhou, China.

Who is sponsoring the NCT05325424 clinical trial?

NCT05325424 is sponsored by Northern Jiangsu People's Hospital. The principal investigator is Guo-Qing Jiang, MD at Clinical Medical College of Yangzhou University. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology